Introduction
Drug-resistant Staphylococcus aureus infections remain a major clinical problem in healthcare settings [1] . Data on the efficacy of therapies for vancomycin-intermediate or vancomycin-resistant Staphylococcus aureus (VISA or VRSA, respectively) are currently limited. Extensive literature has demonstrated efficacy of daptomycin in treating methicillin-resistant Staphylococcus aureus (MRSA). In vitro data additionally indicate activity of daptomycin Both blood cultures drawn upon hospital admission revealed Staphylococcus aureus. Cefepime was discontinued and vancomycin monotherapy was continued. On hospital day 2, the patient's dialysis catheter was removed due to concern for a central line-associated bloodstream infection. Blood cultures identified MRSA with a vancomycin minimum inhibitory concentration (MIC) of 2 μg/ mL, indicating susceptibility by broth microdilution testing (Trek Diagnostic Systems, Cleveland, OH). The vancomycin MIC was confirmed by Epsilometer test (Etest; B Biodisk North America, Piscataway, NJ). Daptomycin MIC was 4 μg/mL, indicating DNS MRSA. Blood cultures drawn on day 2 were also positive for DNS MRSA.
Given persistent bacteremia, on day 4, a transthoracic echocardiogram (TTE) was done. The study was of average quality, visualized all valves, and did not show valvular vegetations. On day 5 a full-spine MRI was negative for vertebral osteomyelitis or spinal epidural infection. Blood cultures on day 5 were no growth. On day 6, due to persistent left shoulder pain, an MRI was done and showed a glenohumoral effusion, erosion of the glenoid surface and mild irregularity of the medial humeral head cortical surface, raising concern for septic arthritis. Shoulder joint aspiration showed WBC 40,500 × 10 6 cells/L, and synovial fluid bacterial culture grew MRSA (vancomycin MIC = 2 μg/mL, daptomycin MIC = 4 μg/mL). On day 7, operative debridement of the left shoulder was performed, and joint fluid cultures again grew MRSA. A trans-esophageal echocardiogram at that time revealed a 1.8 × 0.8 cm independently mobile mitral valve mass with trace mitral regurgitation. No paravalvular abscess or leaflet perforation was present.
Blood cultures on day 9 were again positive, growing recurrent DNS MRSA. Vancomycin trough levels had been adequate: 15 μg/mL on hospital day 5. Vancomycin susceptibility was re-tested by Etest; MIC was 4 μg/mL, indicating vancomycin-intermediate Staphylococcus aureus (VISA). Daptomycin MIC was repeated and again was 4 μg/mL, indicating DNS VISA.
On day 11, blood cultures showed persistent DNS VISA. Ceftaroline sensitivity testing was ordered, and vancomycin was switched to empiric ceftaroline (500 mg load, then 400 mg twice daily, intravenous) plus daptomycin (10 mg/ kg following first and second dialysis session of the week, and 12 mg/kg following third dialysis session of the week). Although mitral valve replacement was indicated, the patient was deemed not to be an operative candidate due to end-stage renal disease, diabetes, advanced age and limited mobility. The patient also expressed a preference for medical therapy.
The ceftaroline MIC from the culture taken on day 9 was 0.5 μg/mL, consistent with antibiotic susceptibility. Blood cultures on days 13, 15, 18 and 19 remained positive for DNS VISA, but on day 21 (day 11 of ceftaroline), blood cultures were negative. Subsequent blood cultures on days 23, 25, 27 and 28 also remained negative, consistent with a durable clearance of bacteremia. The patient completed 6 weeks of ceftaroline/daptomycin therapy, and blood cultures 1 and 4 weeks after discontinuation of therapy remained negative.
The patient was readmitted to the hospital 4 weeks after completion of therapy due to palpitations and acute dyspnea, and atrial fibrillation and heart failure were diagnosed. TTE showed a dilated left atrium, progressive mitral regurgitation, and a diminished mitral vegetation size. After reconsideration for mitral valve replacement, the patient was transitioned to palliative-focused care, where she passed away in the subsequent days. Blood cultures during this final hospitalization showed no growth.
Discussion
We report a case of a patient with prolonged dually resistant (vancomycin-intermediate and daptomycin non-susceptible) Staphylococcus aureus bacteremia due to mitral native valve endocarditis that was ultimately cleared on a combination salvage regimen of ceftaroline and daptomycin. Despite clearance of bacteremia, the patient succumbed from presumed valvulopathy-associated heart failure. This is one of only two cases to our knowledge of DNS VISA endocarditis infection in which bacteremia was cleared with a ceftaroline-based regimen.
Although valve replacement was indicated under standard endocarditis management guidelines, our patient was not a candidate for surgical therapy. Our report adds to a growing literature demonstrating that the combination of ceftaroline and daptomycin can achieve clearance of bacteremia, including in situations where surgery is the preferred management and only presumed route to durable cure.
In this case, although the isolate was not susceptible to daptomycin, we combined daptomycin with ceftaroline empirically due to accumulating evidence that concomitant beta-lactam treatment (here, with ceftaroline) might improve susceptibility to daptomycin through attenuation of net positive surface charge thereby increasing daptomycin binding [5, 7, [9] [10] [11] . Ceftaroline activity may have been mutually enhanced due to the phenomenon known as the "seesaw" effect, by which anti-staphylococcal beta-lactam susceptibility increases as lipopeptide (and glycopeptide) susceptibility decreases.
Prior reports on the combined use of daptomycin with anti-staphylococcal beta-lactams show variability in whether or not daptomycin MIC decreases with the addition of beta-lactam. We did not observe this phenomenon of a reduced daptomycin MIC in our patient: both her initial and subsequent blood cultures all showed daptomycin nonsusceptibility; however, we did not perform synergy testing to assess the daptomycin MIC in the presence of ceftaroline.
Literature describing ceftaroline use for patients with endocarditis due to MRSA [6, [9] [10] [11] [12] [13] , VISA [6, 9] , and DNS Staphylococcus aureus [7, 8, 10, [14] [15] [16] is limited (summarized in Table 1 ), but suggests a role for ceftaroline as salvage therapy, either alone or in combination with daptomycin. Daptomycin non-susceptible MRSA is still rare. Prolonged exposure to vancomycin has been shown to be an important risk factor [17] . In varying clinical contexts, DNS MRSA infections have been treated with ceftaroline, linezolid and vancomycin [7, 8] , as well as with daptomycin with adjunctive rifampin [18] or beta-lactams [5] .
Literature on dually resistant DNS VISA endocarditis infections is even sparser. Limited case reports on DNS VISA endocarditis document treatment with regimens including linezolid, telavancin, gentamicin and rifampin, as well as high-dose daptomycin [14, 16] . However, to our knowledge, only one prior patient with DNS VISA endocarditis has been successfully treated with ceftaroline; this patient survived [10] . In that case, the daptomycin resistance was transient; whereas, in our patient the daptomycin resistance was persistent.
In addition to treatment considerations, this case emphasizes the importance of performing MIC testing on vancomycin or daptomycin isolates by multiple methods. The initial broth microdilution MIC result was one dilution lower than the Etest result for vancomycin, consistent with prior literature [19] and particularly true at the MIC cutoff for VISA, where at least two MIC methods are recommended [20] . Also, this patient was prescribed a higher dose of ceftaroline than is normally recommended in hemodialysis (400 mg intravenous every 12 h instead of 200 mg every 12 h). This strategy was used based on limited data suggesting that higher dosing has been effective in MRSA endocarditis [13, 21, 22] .
In summary, we report a patient with dually resistant vancomycin-intermediate/DNS Staphylococcus aureus bacteremia due to mitral valve endocarditis who cleared the bacteremia with a combination of daptomycin and ceftaroline. Although the patient ultimately succumbed to heart failure, and was not a candidate for operative valve replacement, this report adds to a growing body of literature supporting a potential role for ceftaroline/daptomycin in managing difficult highly drug-resistant Staphylococcus aureus infections. Prospectively enrolled clinical studies are needed to better define the benefits of this therapy, as treatment options are often limited in this highly morbid condition. 
